Xarelto (Rivaroxaban) Drug Side Effects Class Action Lawsuit
QC Feb 16, 2015 [en]
Motion for Authorization
CONSUMER LAW GROUP has launched a Canada-wide class action lawsuit against the makers of Xarelto (Rivaroxaban), marketed and sold in Canada by Bayer, Janssen and Johnson & Johnson who have suffered a bleeding event after taking the anticoagulant drug.
- Xarelto is approved to treat deep vein thrombosis and pulmonary embolism, and is sometimes prescribed following hip or knee replacement
- Xarelto has been linked to complications including intestinal bleeding, rectal bleeding, blood clots, brain hemorrhaging, pulmonary embolism, and deep vein thrombosis
- Unlike warfarin, there is no known antidote to stop bleeding caused by this medication
The makers and marketers of XARELTO continues to fail to warn consumers, healthcare professionals and the public:
a. Of the serious and significant risk of serious, severe and irreversible bleeding complications;
b. That in the event of a bleeding complication, there is no antidote to reverse it; and
c. That people taking XARELTO should closely and frequently monitor their blood;
The class action lawsuit identifies the group of affected persons as:
All persons residing in Canada who have taken and/or purchased the drug, RIVAROXABAN (sold under the brand name XARELTO) since 2008, and their successors, assigns, family members, and dependants, or any other group to be determined by the Court;
The Food and Drug Administration received 680 reports of adverse events in Xarelto users in 2013, according to Digital Journal. Meanwhile, in Bayer’s home country of Germany, the newspaper Der Spiegel reported that, between January 2012 and September 2013, Xarelto was linked in Germany to 130 deaths along with 1,700 serious complications. According to news reports, Xarelto may be responsible for 1,400 deaths.
The most serious problem associated with Xarelto and similar medications is fatal hemorrhaging. When a patient on the medication starts bleeding from even a minor injury (including a bump on the head), there is virtually no way to stop it.
The reason for this lies in the drug’s mechanism of action. Blood coagulation is dependent on the action of Vitamin K (naturally occurring in leafy greens and cruciferous vegetables such as cabbage) in order to produce the clotting agent thrombin. Warfarin disables Vitamin K, so any serious bleeding can be halted with high dosages of this vitamin. Xarelto prevents the production of Vitamin K altogether; therefore, once a patient starts hemorrhaging, there is virtually no way to stop it.
Other potentially serious side effects include diarrhea, arrhythmia (irregular heartbeat), tachycardia (racing heartbeat) and wide, sudden changes in blood pressure. Though not always life-threatening, these symptoms can be serious if the patient does not receive prompt medical treatment.
Xarelto patients also report burning or itching/tingling sensations on the skin, numbness and back pain. Additional side effects include lower gastrointestinal or bladder problems, difficulty in swallowing, headaches and dizziness and weakness or pain in the extremities. Some patients have experienced fainting and muscular spasms.
If you or a member of your family have used the drug Xarelto and were subsequently injured, and you wish more information on potential compensation or to be kept advised of the status of the Xarelto (Rivaroxaban) Drug Side Effects Class Action litigation or any resulting compensation from the Xarelto (Rivaroxaban) Drug Side Effects Lawsuit in Canada, Quebec or Ontario, please provide your contact information to our law firm using the below form.
IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.